Back to search
Plasmablastic Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Plasmablastic Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Plasmablastic Lymphoma trials you may qualify forBackground: Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are aggressive forms of cancer that affects…
Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more lik…
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or rec…
It is an open-label, multicenter, phase II, single arm trial to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in…
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment…
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in…
RATIONALE: Giving high-dose chemotherapy drugs, such as carmustine, etoposide, and cyclophosphamide, before a peripheral blood stem cell transplant stops the gr…
This phase Ib trial tests the safety, side effects, and best dose, as well as the effectiveness of teclistamab in treating patients with plasmablastic lymphoma…